Diverse Biotech to Focus in FDA Clinical trial
ORLANDO, FL | June 4th, 2018 Diverse Biotech Inc., is a private biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it is pursuing preclinical studies of a pipeline compound BRCX014 in adult patients with Glioblastoma. BRCX014 is also being developed within the field of Myeloma which will represent an increased therapeutic focus for ongoing development of this pipeline compound.
In parallel with this study, Diverse Biotech has been evaluating BRCX014 in pre-clinical models of Basal and Squamous cell carcinoma yielding promising signals on clinical endpoints. Diverse Biotech R&D focus has evolved in the last year towards specific cancers where we have generated significant positive clinical data.